Intranasal CRMP2-Ubc9 Inhibitor Regulates NaV1.7 to Alleviate Trigeminal Neuropathic Pain
暂无分享,去创建一个
Heather N. Allen | Saumya Saurabh | Aida Calderón-Rivera | Kimberly Gomez | Paz Duran | R. Khanna | Upasana Kumar | Santiago I. Loya-López | Olga A. Korczeniewska | Rory Shields | Rui Zeng | Akshat Dwivedi | Santiago I Loya-Lopez
[1] Heather N. Allen,et al. Neuropilin-1 is essential for vascular endothelial growth factor A-mediated increase of sensory neuron activity and development of pain-like behaviors. , 2023, Pain.
[2] G. Zamponi,et al. Electrophysiological and computational analysis of Cav3.2 channel variants associated with familial trigeminal neuralgia , 2022, Molecular Brain.
[3] Aida Calderón-Rivera,et al. Cell specific regulation of NaV1.7 activity and trafficking in rat nodose ganglia neurons , 2022, Neurobiology of pain.
[4] Romain F. Laine,et al. TrackMate 7: integrating state-of-the-art segmentation algorithms into tracking pipelines , 2022, Nature Methods.
[5] Peng Zhang,et al. Prolonged PGE2 treatment increased TTX-sensitive but not TTX-resistant sodium current in trigeminal ganglionic neurons , 2022, Neuropharmacology.
[6] G. Zamponi,et al. CaV3.2 calcium channels contribute to trigeminal neuralgia. , 2022, Pain.
[7] R. Khanna,et al. Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats , 2022, Channels.
[8] R. Khanna,et al. Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces and prevents pain chronification in a mouse model of oxaliplatin-induced neuropathic pain , 2021, Neurobiology of Pain.
[9] A. Hohmann,et al. Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents , 2021, Science Translational Medicine.
[10] R. Khanna,et al. CRMP2 Is Involved in Regulation of Mitochondrial Morphology and Motility in Neurons , 2021, Cells.
[11] Vimala N. Bharadwaj,et al. Intranasal Administration for Pain: Oxytocin and Other Polypeptides , 2021, Pharmaceutics.
[12] R. Khanna,et al. Non-SUMOylated CRMP2 decreases NaV1.7 currents via the endocytic proteins Numb, Nedd4-2 and Eps15 , 2021, Molecular brain.
[13] J. Gerrard,et al. Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal Neuralgia , 2020, iScience.
[14] R. Khanna,et al. Studies on CRMP2 SUMOylation-deficient transgenic mice identify sex-specific NaV1.7 regulation in the pathogenesis of chronic neuropathic pain , 2020, bioRxiv.
[15] R. Benoliel,et al. Differential gene expression changes in the dorsal root versus trigeminal ganglia following peripheral nerve injury in rats , 2020, European journal of pain.
[16] Donal N. Gorman,et al. Lack of Detection of the Analgesic Properties of PF‐05089771, a Selective Nav1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects , 2019, Clinical and translational science.
[17] S. Dib-Hajj,et al. Building sensory axons: Delivery and distribution of NaV1.7 channels and effects of inflammatory mediators , 2019, Science Advances.
[18] R. Khanna,et al. Mining the Nav1.7 interactome: Opportunities for chronic pain therapeutics. , 2019, Biochemical pharmacology.
[19] A. M. Rush,et al. The role of Nav1.7 in human nociceptors: insights from human induced pluripotent stem cell–derived sensory neurons of erythromelalgia patients , 2019, Pain.
[20] M. Khanna,et al. Blocking CRMP2 SUMOylation reverses neuropathic pain , 2018, Molecular Psychiatry.
[21] Yue Wang,et al. Inhibition of the Ubc9 E2 SUMO-conjugating enzyme–CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain , 2018, Pain.
[22] M. Khanna,et al. Betulinic acid, derived from the desert lavender Hyptis emoryi, attenuates paclitaxel-, HIV-, and nerve injury–associated peripheral sensory neuropathy via block of N- and T-type calcium channels , 2018, Pain.
[23] A. McDonnell,et al. Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy , 2018, Pain.
[24] R. Khanna,et al. Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain , 2018, Neurobiology of pain.
[25] K. Messlinger,et al. Current understanding of trigeminal ganglion structure and function in headache , 2018, Cephalalgia : an international journal of headache.
[26] Yue Wang,et al. Homology‐guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2‐derived peptides , 2018, British journal of pharmacology.
[27] R. Khanna,et al. CRMP2 and voltage-gated ion channels: potential roles in neuropathic pain , 2018, Neuronal signaling.
[28] M. Khanna,et al. Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels , 2018, Channels.
[29] Ki Duk Park,et al. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide , 2017, Pain.
[30] Yue Wang,et al. Dissecting the role of the CRMP2–neurofibromin complex on pain behaviors , 2017, Pain.
[31] J. Olesen,et al. Whole transcriptome expression of trigeminal ganglia compared to dorsal root ganglia in Rattus Norvegicus , 2017, Neuroscience.
[32] M. Khanna,et al. A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function , 2017, Channels.
[33] M. Khanna,et al. Hierarchical CRMP2 posttranslational modifications control NaV1.7 function , 2016, Proceedings of the National Academy of Sciences.
[34] Ki Duk Park,et al. Efficacy of (S)-lacosamide in preclinical models of cephalic pain , 2016, Pain reports.
[35] J. Wood,et al. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief , 2016, Expert opinion on therapeutic targets.
[36] M. Bruchez,et al. Kinetically Tunable Photostability of Fluorogen-Activating Peptide-Fluorogen Complexes. , 2015, Chemphyschem : a European journal of chemical physics and physical chemistry.
[37] M. Khanna,et al. A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors , 2015, Pain.
[38] Cai-yue Liu,et al. The role of large-conductance, calcium-activated potassium channels in a rat model of trigeminal neuropathic pain , 2015, Cephalalgia : an international journal of headache.
[39] Guy M. Hagen,et al. ThunderSTORM: a comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution imaging , 2014, Bioinform..
[40] Stephen G Waxman,et al. Regulating excitability of peripheral afferents: emerging ion channel targets , 2014, Nature Neuroscience.
[41] Jared G. Smith,et al. The psychosocial and affective burden of posttraumatic neuropathy following injuries to the trigeminal nerve. , 2013, Journal of orofacial pain.
[42] T. Kanazawa,et al. Suppression of ATP-induced excitability in rat small-diameter trigeminal ganglion neurons by activation of GABAB receptor , 2013, Brain Research Bulletin.
[43] Sarah M. Wilson,et al. CRMP2 Protein SUMOylation Modulates NaV1.7 Channel Trafficking* , 2013, The Journal of Biological Chemistry.
[44] T. Kanazawa,et al. Brain-derived neurotrophic factor enhances the excitability of small-diameter trigeminal ganglion neurons projecting to the trigeminal nucleus interpolaris/caudalis transition zone following masseter muscle inflammation , 2013, Molecular pain.
[45] S. Dib-Hajj,et al. The NaV1.7 sodium channel: from molecule to man , 2012, Nature Reviews Neuroscience.
[46] Euiseong Kim,et al. Hypoesthesia after IAN block anesthesia with lidocaine: management of mild to moderate nerve injury , 2012, Restorative dentistry & endodontics.
[47] Y. Wang,et al. Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization , 2012, Neuroscience.
[48] S. Meroueh,et al. CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy , 2012, Molecular pain.
[49] S. Meroueh,et al. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca2+ channel complex , 2011, Nature Medicine.
[50] G. Klasser,et al. The prevalence of persistent pain after nonsurgical root canal treatment. , 2011, Quintessence international.
[51] T. Renton,et al. Trigeminal nerve injuries in relation to the local anaesthesia in mandibular injections , 2010, BDJ.
[52] X. Michalet. Mean square displacement analysis of single-particle trajectories with localization error: Brownian motion in an isotropic medium. , 2010, Physical review. E, Statistical, nonlinear, and soft matter physics.
[53] W. Frey,et al. Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. , 2010, Molecular pharmaceutics.
[54] W. Frey,et al. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. , 2010, Journal of pharmaceutical sciences.
[55] J. Hodges,et al. Frequency of persistent tooth pain after root canal therapy: a systematic review and meta-analysis , 2010, BDJ.
[56] R. Khanna,et al. Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons , 2009, Journal of Cell Science.
[57] R. Khanna,et al. An Atypical Role for Collapsin Response Mediator Protein 2 (CRMP-2) in Neurotransmitter Release via Interaction with Presynaptic Voltage-gated Calcium Channels* , 2009, The Journal of Biological Chemistry.
[58] J. Henley,et al. Protein SUMOylation in neuropathological conditions. , 2009, Drug news & perspectives.
[59] Martin Koltzenburg,et al. ProTx-II, a Selective Inhibitor of NaV1.7 Sodium Channels, Blocks Action Potential Propagation in Nociceptors , 2008, Molecular Pharmacology.
[60] James A J Fitzpatrick,et al. Fluorogen-activating single-chain antibodies for imaging cell surface proteins , 2008, Nature Biotechnology.
[61] S. Hoka,et al. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. , 2006, British journal of anaesthesia.
[62] Miller H. Smith,et al. Nerve injuries after dental injection: a review of the literature. , 2006, Journal.
[63] E. Valmaseda-Castellón,et al. Frequency and evolution of lingual nerve lesions following lower third molar extraction. , 2006, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[64] P. Goadsby,et al. Calcium channels modulate nociceptive transmission in the trigeminal nucleus of the cat , 2005, Neuroscience.
[65] B. Vasconcelos,et al. Lingual nerve damage after mandibular third molar surgery: a randomized clinical trial. , 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[66] A. Plückthun,et al. A mutation designed to alter crystal packing permits structural analysis of a tight‐binding fluorescein–scFv complex , 2005, Protein science : a publication of the Protein Society.
[67] H. Schaible,et al. Effects of N-, P/Q- and L-type Calcium Channel Blockers on Nociceptive Neurones of the Trigeminal Nucleus with Input from the Dura , 2004, Cephalalgia : an international journal of headache.
[68] R. Benoliel,et al. Application of a pro-inflammatory agent to the orbital portion of the rat infraorbital nerve induces changes indicative of ongoing trigeminal pain , 2002, Pain.
[69] E. Valmaseda-Castellón,et al. Inferior alveolar nerve damage after lower third molar surgical extraction: a prospective study of 1117 surgical extractions. , 2001, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[70] J. Gregg. Neuropathic complications of mandibular implant surgery: review and case presentations. , 2000, Annals of the Royal Australasian College of Dental Surgeons.
[71] T. Nurmikko,et al. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial , 1997, Pain.
[72] H. Kawamoto,et al. Characterization of heat-hyperalgesia in an experimental trigeminal neuropathy in rats , 1997, Experimental Brain Research.
[73] B. Vos,et al. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[74] B. van der Dijs,et al. Pimozide therapy for trigeminal neuralgia. , 1989, Archives of neurology.
[75] G. Fromm,et al. Baclofen in the treatment of trigeminal neuralgia: Double‐blind study and long‐term follow‐up , 1984, Annals of neurology.
[76] J. Ballantyne,et al. Painful Traumatic Trigeminal Neuropathy , 2014 .
[77] P. Svensson,et al. Seven-year follow-up of patients diagnosed with atypical odontalgia: a prospective study. , 2013, Journal of orofacial pain.
[78] Y. Sharav,et al. Peripheral painful traumatic trigeminal neuropathy: clinical features in 91 cases and proposal of novel diagnostic criteria. , 2012, Journal of orofacial pain.
[79] M. Takeda,et al. Prostaglandin E2 potentiates the excitability of small diameter trigeminal root ganglion neurons projecting onto the superficial layer of the cervical dorsal horn in rats , 2006, Experimental Brain Research.
[80] R. Gracely,et al. Effect of dexamethasone and dipyrone on lingual and inferior alveolar nerve hypersensitivity following third molar extractions: preliminary report. , 2004, Journal of orofacial pain.
[81] R. Young,et al. Unmyelinated axons in the trigeminal motor root of human and cat , 1979, The Journal of comparative neurology.